Stansky Michael P
SEC CIK 1424204 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | Dir | 1.24M | $3.01M | — | 5 | 2026-02-23 | 2026-05-15 |
Most active insiders at TLSI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Stansky Michael P | Dir | $3.01M | — |
| 2 | Szela Mary T | CEO, Pres, Dir | $227.8K | $79.4K |
| 3 | Wahlstrom Mats | Dir | $151.8K | — |
| 4 | Valle William | Dir | $125.0K | — |
| 5 | Gordon Gary B. | Dir | $64.6K | — |
| 6 | Patience David | CFO | $32.2K | — |
| 7 | Marshak Richard | Chief Commercial Off | — | $15.7K |
| 8 | Stevens Jennifer | Chief Regulatory Off | — | $14.5K |
| 9 | Devlin Jodi | Chief of Clinical Ops | — | $13.2K |
| 10 | Cox Bryan F. | Chief of Research | — | $13.1K |
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 16:42 | 2026-05-15 | TLSI | TriSalus Life Sciences, Inc. | Stansky Michael P | Dir | P - Purchase | $2.50 | +410.0K | 1.24M | +49% | +$1.02M | |
| I | 2026-05-18 16:42 | 2026-05-15 | TLSI | TriSalus Life Sciences, Inc. | Stansky Michael P | Dir | P - Purchase | $2.50 | +200.0K | 399.7K | +100% | +$500.0K |
| DM | 2026-05-15 16:39 | 2026-05-14 | TLSI | TriSalus Life Sciences, Inc. | Stansky Michael P | Dir | A - Grant | $0.00 | +43.6K | 830.7K | +6% | $0 |
| 2026-02-23 | 2026-02-23 | TLSI | TriSalus Life Sciences, Inc. | Stansky Michael P | Dir | P - Purchase | $4.10 | +243.9K | 787.1K | +45% | +$1000.0K | |
| I | 2026-02-23 | 2026-02-23 | TLSI | TriSalus Life Sciences, Inc. | Stansky Michael P | Dir | P - Purchase | $4.10 | +117.2K | 199.7K | +142% | +$480.5K |
Purchase Sale Sale after option exercise All abbreviations